Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Abstract

This disclosure provides compounds of Formula (I) (e.g., Formula (I-1) (e.g., (I-a1), (I-b1), (I-b3), (I-c1), (I-d1), (I-e1), (I-e3), (I-f1), (I-g1), (I-g3), (I-h1), (I-i1), or (I-i3)) or Formula (I-2) (e.g., (I-a2), (I-b2), (I-b4), (I-c2), (I-d2), (I-e2), (I-e4), (I-f2), (I-g2), (I-g4), (I-h2), or (I-i2))), Formula (II) (e.g., Formula (II-a1) or (II-a2)), or Formula (A), or a pharmaceutically acceptable salt thereof, that induce degradation of a BCL-XL protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds, or pharmaceutically acceptable salts thereof, provided herein as well as methods of using and making the same.

Dependencies are inferred from the claim text.